![]() |
|
|
Vol. 286, Issue 2, 676-680, August 1998
Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan
| |
Abstract |
|---|
|
|
|---|
To clarify the mechanisms of the renal tubular secretion of nicotine, we studied transport of nicotine in the kidney epithelial cell line LLC-PK1. The transcellular transport of nicotine from the basolateral side to the apical side of the LLC-PK1 monolayers grown on membrane filters was much greater than that of tetraethylammonium. The basolateral-to-apical transport of nicotine was stimulated by lowering the pH of the apical side, accompanied by a decrease in the accumulation of nicotine. The accumulation of nicotine from the basolateral side was inhibited by unlabeled nicotine, cotinine, tetraethylammonium, cimetidine and quinidine. The uptake of nicotine across the apical membrane was inhibited by unlabeled nicotine and quinidine but not by tetraethylammonium or cimetidine. Pretreatment with p-chloromercuribenzene sulfonate caused a decrease in the transcellular transport of tetraethylammonium but not of nicotine. These results suggest that nicotine undergoes vectorial transport from basolateral side to the apical side of LLC-PK1 monolayers in a H+ gradient-dependent manner, corresponding to the secretion in the renal tubules. Nicotine transport in LLC-PK1 cells could be mediated by a transport system that is distinct from the transport system for tetraethylammonium.
| |
Introduction |
|---|
|
|
|---|
Nicotine
is consumed widely by tobacco smokers and in therapeutic
pharmaceuticals such as nicotine-resin chewing gum. Nicotine consists
of a pyridine and a pyrrolidine ring, thereby being a weak base
(pKa = 7.9) (Beckett et al.,
1972
). The major elimination route of nicotine is its extensive
metabolism in the liver (Kyerematen and Vesell, 1991
; Plowchalk
et al., 1992
). In addition to the hepatic metabolism, both
the parent nicotine and its metabolites are excreted into the urine not
only by glomerular filtration but also by active tubular secretion
(Svensson, 1987
). Nicotine is excreted in urine in a pH-dependent
manner (Benowitz and Jacob III, 1985
; Rosenberg et al.,
1980
). At urinary pH levels of >7, nicotine is reabsorbed by the renal
tubules and only 2% of a dose is excreted unchanged in urine. At
urinary pH levels of <5, ~23% of the nicotine dose is recovered in
urine (Rosenberg et al., 1980
). Although this pH-dependent
renal handling of nicotine has been thought to follow the predictions
of the Henderson-Hasselbach equation, the precise mechanisms involved
in the tubular secretion and reabsorption of nicotine have not yet been
fully characterized. Nicotine has been reported to interact
with an organic cation transport system in renal tubules (Bendayan
et al., 1990a
; Ullrich et al., 1993
; Wong
et al., 1991
). Renal nicotine clearance was decreased by
cimetidine, an organic cation (Bendayan et al., 1990b
), but
it is unknown whether the organic cation transport systems expressed in
the tubular cells are involved in the renal secretion of nicotine.
LLC-PK1 cells, derived from the pig kidney, have
been used for studies of the transepithelial transport and accumulation
of cationic molecules and drug interactions (Bendayan et
al., 1994
; McKinney et al., 1992
; Ohtomo et
al., 1996
; Saito et al., 1992
). We obtained the first
evidence that the apical membranes of the LLC-PK1
cells express the H+/organic cation antiporter
(Inui et al., 1985
). In addition, we reported that
LLC-PK1 cell monolayers grown on porous membrane filters showed a unidirectional transcellular transport of the typical
cation tetraethylammonium from the basolateral side to the apical side,
corresponding to the secretion in the renal proximal tubules (Saito
et al., 1992
).
In the present study, we investigated the mechanisms underlying the transcellular transport of nicotine in the LLC-PK1 cell monolayers, and we obtained the first evidence showing that the H+ gradient-dependent transcellular transport of nicotine is mediated by apically and basolaterally localized organic cation transport systems, which are distinct from the transport systems for tetraethylammonium in the LLC-PK1 cells.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
[14C]Tetraethylammonium bromide
(124 MBq/mmol), (
)-[3H]nicotine (2,900 GBq/mmol),
D-[3H]mannitol (729 GBq/mmol) and
D-[14C]mannitol (1.9 GBq/mmol) were purchased
from DuPont-New England Nuclear Research Products (Boston, MA).
Nicotine was obtained from Wako Pure Chemical Industries (Osaka,
Japan). Cotinine and N1-methylnicotinamide were purchased
from Sigma Chemical (St. Louis, MO). Tetraethylammonium chloride,
cimetidine, quinidine sulfate and PCMBS were from Nacalai Tesque
(Kyoto, Japan). Levofloxacin was kindly supplied by Daiichi Seiyaku
(Tokyo, Japan). All other chemicals were of the highest purity
available.
Cell culture.
Cells of the porcine kidney epithelial cell
line LLC-PK1, obtained from the American Type
Culture Collection (ATCC CRL-1392; Rockville, MD), were grown on
plastic dishes in Dulbecco's modified Eagle's medium (GIBCO Life
Technologies, Grand Island, NY), supplemented with 10% fetal calf
serum (Whittaker Bioproducts, Walkersville, MD) without antibiotics in
an atmosphere of 5% CO2/95% air at 37°C
(Saito et al., 1992
). For the transport experiments, the cells were seeded on microporous membrane filters (3-µm pores, 4.71-cm2 growth area) inside a Transwell cell
culture chamber (Costar, Cambridge, MA) at a cell density of 5 × 105 cells/cm2. In this
study, LLC-PK1 cells between the 212th and 220th
passages were used.
Measurements of transcellular transport and cellular accumulation
of nicotine and tetraethylammonium.
The transcellular transport
and cellular accumulation of radioactive drugs were measured in
monolayer cultures grown in the Transwell chamber. The incubation
medium for uptake experiments was Dulbecco's phosphate-buffered saline
(pH 7.4) (buffer: 137 mM NaCl, 3 mM KCl, 8 mM
Na2HPO4, 1.5 mM
KH2PO4, 1 mM
CaCl2 and 0.5 mM MgCl2),
containing 5 mM D-glucose. In the general experiments, the
transcellular transport and cellular accumulation were measured as
described previously (Saito et al., 1992
). Briefly, after
the removal of culture medium from both sides of the monolayers, the cell monolayers preincubated with 2 ml of incubation medium containing [3H]nicotine (12.5 or 25 nM, 37 or 74 kBq/ml)
or [14C]tetraethylammonium (50 µM, 6.3 kBq/ml) and D-[14C]mannitol (3.9 µM, 7.4 kBq/ml) or D-[3H]mannitol
(6.4 µM, 29.6 kBq/ml) were added to the basolateral or apical side of
the monolayers, and 2 ml of radioactivity-free incubation medium was
added to the opposite side. The cell monolayers were incubated for the
specified periods of time at 37°C. Labeled D-mannitol was
used to estimate the paracellular fluxes and the extracellular trapping
of labeled drugs. For the transport measurements, an aliquot (50 µl)
of the incubation medium in the other side was taken at the specified
time, and the radioactivity was determined. For accumulation
measurements, the medium was removed by suction at the end of the
incubation period, and the monolayers were rapidly washed two times
with 2 ml of ice-cold incubation medium on each side. The filters with
monolayers were detached from the chambers, the cells on the filters
were solubilized in 0.5 ml of 1 N NaOH, and the radioactivity of each
aliquot (200 µl) was determined. The radioactivity of the collected
media and the solubilized cell monolayers were determined in 5 ml of
ACS II (Amersham International, Buckinghamshire, UK) by liquid
scintillation counting. The protein content of the solubilized cell
monolayers was determined by the method of Bradford (Bradford, 1976
),
using the BioRad Protein Assay Kit with bovine
-globulin as the
standard. The protein content of the monolayers was 0.94 to 1.45 mg/filter (4.71 cm2).
Statistical analysis. Data were analyzed using one-way analysis of variance followed by Fisher's t test. Probability values of <5% were considered significant.
| |
Results |
|---|
|
|
|---|
Transcellular transport and cellular accumulation of tetraethylammonium and nicotine. We measured the transcellular transport and cellular accumulation of [14C]tetraethylammonium and [3H]nicotine by the monolayers of LLC-PK1 cells grown on filters in a Transwell chamber in the presence of an inward H+ gradient (apical side, pH 6.0; basolateral side, pH 7.4). As shown in figure 1, the basolateral-to-apical transports of [14C]tetraethylammonium and [3H]nicotine were much higher than the apical-to-basolateral transport of each drug, suggesting that both drugs were subjected to unidirectional transcellular transport in the LLC-PK1 cells, corresponding to the renal tubular secretion. The cellular accumulation of [14C]tetraethylammonium from the basolateral side for 60 min was 3-fold higher than that from the apical side (fig. 1B). In contrast, the accumulation of [3H]nicotine from the basolateral side was smaller than that from the apical side (fig. 1D), suggesting that the uptake of nicotine occurred across the apical membranes of the LLC-PK1 cells.
|
Effect of the apical side pH.
It is well known that the renal
excretion of nicotine is urine pH dependent (Rosenberg et
al., 1980
). When urine becomes more acidic (pH <5), as much as
23% of a dose can be recovered unchanged in the urine. To determine
whether this pH-dependent manner of nicotine secretion in
vivo would take place in LLC-PK1 cells, we
examined the effect of pH of the incubation medium on the transcellular transport and accumulation of nicotine. Figure
2 illustrates the pH dependence of the
[3H]nicotine transport and accumulation. The
basolateral-to-apical transport of [3H]nicotine
was markedly increased by lowering the pH of the apical side (the
basolateral side pH was fixed to 7.4), accompanied by a decrease in the
accumulation in the monolayers. These results suggested that the
transcellular transport of nicotine is dependent mainly on the pH of
the apical side and that the antiport of nicotine with
H+ is involved in the efflux of nicotine out of
LLC-PK1 cells.
|
Concentration dependence of nicotine accumulation.
Figure
3 shows the cellular accumulation of
[3H]nicotine and
[14C]tetraethylammonium from the basolateral
side of the LLC-PK1 cell monolayers as a function
of an increased concentration of the substrate. The curves for the
accumulation of both drugs were curvilinear, indicating a saturable
process. The apparent Michaelis constant
(Km) and maximum velocity
(Vmax) values of the accumulation of
[3H]nicotine, estimated from the
Michaelis-Menten equation using a nonlinear least-squares analysis
(Yamaoka et al., 1981
), were 360 µM and 916 pmol/mg of
protein/min, respectively. The Km and Vmax values for
[14C]tetraethylammonium were 296 µM and 592 pmol/mg of protein/min, respectively. The
Kd value (a parameter for the diffusion
component) of [14C]tetraethylammonium was
negligible, whereas the Kd value of
[3H]nicotine was 206 pmol/mg of protein/min/mM.
|
Effects of cationic drugs on tetraethylammonium and nicotine accumulation. To examine the substrate specificity of the transport systems mediating the cellular accumulation of nicotine and/or tetraethylammonium in LLC-PK1 cells, we evaluated the effects of various cationic compounds added to the basolateral or apical side on the accumulation of [14C]tetraethylammonium and [3H]nicotine from the basolateral and apical sides of the monolayers. As depicted in figure 4, cationic drugs such as unlabeled nicotine, tetraethylammonium, cimetidine and quinidine showed potent inhibitory effects on the accumulation of both drugs from the basolateral side. N1-Methylnicotinamide, an endogenous cation, had no significant effect on the accumulation. Cotinine, a major metabolite of nicotine, showed a potent inhibitory effect on the accumulation of [3H]nicotine but not on that of [14C]tetraethylammonium. In contrast, the [14C]tetraethylammonium accumulation from the apical side was potently inhibited in the presence of nicotine and quinidine, and weakly but significantly inhibited in the presence of unlabeled tetraethylammonium and cimetidine (fig. 5). Furthermore, the [3H]nicotine accumulation from the apical side was markedly inhibited in the presence of unlabeled nicotine or quinidine, whereas the accumulation was not inhibited in the presence of unlabeled tetraethylammonium, cimetidine or N1-methylnicotinamide.
|
|
Effects of PCMBS on transcellular transport of tetraethylammonium
and nicotine.
We previously reported that sulfhydryl groups are
essential for the organic cation transport systems expressed in both
the apical and basolateral membranes of LLC-PK1
cells (Saito et al., 1992
). In this study, we examined the
effect of PCMBS on the transcellular transport and accumulation of
[14C]tetraethylammonium and
[3H]nicotine. As illustrated in figure
6, the apical pretreatment with PCMBS
caused a marked decrease in the basolateral-to-apical transport of
[14C]tetraethylammonium, which was accompanied
by an increase in the cellular accumulation. The pretreatment of the
basolateral membranes with PCMBS had weak and not significant effect on
the [14C]tetraethylammonium transport and
accumulation. In contrast, the transcellular transport and accumulation
of [3H]nicotine were not affected by the PCMBS
pretreatment of the basolateral and apical membranes, suggesting that
the transport systems for nicotine are almost insensitive to sulfhydryl
modification.
|
| |
Discussion |
|---|
|
|
|---|
To clarify the mechanisms of the renal tubular secretion of
nicotine, we examined the transcellular transport and cellular accumulation of nicotine by using cell monolayers of the porcine kidney
epithelial cell line LLC-PK1. It has been well
documented that nicotine is both reabsorbed and secreted in the human
renal tubules (Rosenberg et al., 1980
; Svensson, 1987
),
although processes involved in the nicotine transport through renal
basolateral and brush-border membranes have not yet been characterized.
We previously reported that the LLC-PK1 cells
express organic cation transporters in both the basolateral and apical
membranes and that tetraethylammonium was transported unidirectionally
from the basolateral side to the apical side across monolayers grown on
porous membrane filters (Saito et al., 1992
). The apically
localized H+/organic cation antiporter was found
to mediate the TEA efflux out of the cells in the apical membranes
(Inui et al., 1985
).
In the present study, we observed that both tetraethylammonium
and nicotine were transported directionally from the basolateral side
to the apical side in the presence of an inward
H+ gradient on the apical membranes,
corresponding to renal tubular secretion (fig. 1). The pH-dependent
transcellular transport of nicotine is consistent with the urine
pH-dependent excretion of nicotine in the kidney (Rosenberg et
al., 1980
). The pH dependence of the nicotine transport across
LLC-PK1 cell monolayers could be explained by the
following possibilities. First, nicotine is taken up into the monolayer
across the basolateral membrane and transported across the apical
membrane via the H+/organic cation
antiport system; an imposed H+ gradient could
drive the efflux of intracellular nicotine out of the cells, as has
been observed for tetraethylammonium transport. Second, nicotine
follows the Henderson-Hasselbach equation based on a pH partition
theory. This possibility can be supported by the finding that ionized
nicotine with lower permeability is increased by the lowering pH of the
apical side, thereby resulting in an accelerated cell-to-apical passive
diffusion of nonionized nicotine. This would not be the case for
tetraethylammonium because tetraethylammonium exists mostly in a
cationic form with the pKa value of 11 and is unable to easily permeate cell membranes due to its low lipid
solubility. However, the present findings that the apical uptake of
nicotine was inhibited by the presence of unlabeled nicotine, quinidine
and levofloxacin suggest that the apical transport of nicotine may be
mediated by a specific transport system or systems rather than by
passive diffusion.
We previously reported that cimetidine may share a common transport
system with tetraethylammonium in the rat renal membrane vesicles
(Takano et al., 1985
). In the present study, cimetidine inhibited the tetraethylammonium uptake at the basolateral and apical
membranes in LLC-PK1 monolayers. However,
cimetidine had a weak inhibitory effect on the nicotine uptake from the
basolateral membranes and no effect on that from apical membranes.
Together with these findings, nicotine transport in apical and
basolateral membranes of LLC-PK1 cells could be
mediated by distinct transport systems from those for
tetraethylammonium and cimetidine.
The most distinct feature of the transport characteristics between
tetraethylammonium and nicotine was the PCMBS sensitivities. The PCMBS
treatment of LLC-PK1 monolayers caused a marked
depression of tetraethylammonium transport, especially at the apical
membranes, being consistent with the previous finding that the
H+/organic cation antiport system in the renal
brush-border membranes was highly sensitive to PCMBS (Saito et
al., 1992
). In contrast, the nicotine transport was not affected
by PCMBS (fig. 6), suggesting that the apical membrane transport system
involved in nicotine efflux differs from the system that mediates
tetraethylammonium efflux. It is as yet unknown whether the transport
system mediating the transcellular transport of nicotine in
LLC-PK1 cells is an "organic cation transport
system" or another type of specific transport system.
In conclusion, nicotine was accumulated across the basolateral membrane via a specific transport system and underwent efflux across the apical membranes in a pH-dependent manner, corresponding to urine pH-dependent tubular excretion, and was mediated by a transport system distinct from the organic cation system for TEA in the LLC-PK1 cells. To our knowledge, this is the first report describing cellular mechanisms of nicotine secretion in renal epithelia. In addition, LLC-PK1 cells can serve an in vitro model for the prediction and evaluation of renal interactions between nicotine and a wide variety of cationic drugs.
| |
Footnotes |
|---|
Accepted for publication April 7, 1998.
Received for publication November 28, 1997.
1 This work was supported in part by a Grant-in-Aid for Scientific Research (B) from the Ministry of Education, Science, and Culture of Japan and by the Smoking Research Foundation.
Send reprint requests to: Ken-ichi Inui, Ph.D., Department of Pharmacy, Kyoto University Hospital, Sakyo-ku, Kyoto 606-8507, Japan.
| |
Abbreviation |
|---|
PCMBS, p-chloromercuribenzene sulfonate.
| |
References |
|---|
|
|
|---|
)- and (+)-nicotine at concentrations documented in plasma of habitual tobacco smokers.
J Pharmacol Exp Ther
261:
21-25This article has been cited by other articles:
![]() |
J. Hukkanen, P. Jacob III, and N. L. Benowitz Metabolism and Disposition Kinetics of Nicotine Pharmacol. Rev., March 1, 2005; 57(1): 79 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Wright and W. H. Dantzler Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport Physiol Rev, July 1, 2004; 84(3): 987 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fukada, H. Saito, and K.-i. Inui Transport Mechanisms of Nicotine across the Human Intestinal Epithelial Cell Line Caco-2 J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 532 - 538. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Goralski and D. S. Sitar Tetraethylammonium and Amantadine Identify Distinct Organic Cation Transporters in Rat Renal Cortical Proximal and Distal Tubules J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 295 - 302. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||